Olmesartan/Amlodipin/Hydrochlorthiazid Krka (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipin/Hydrochlorthiazid Krka is used in the management of hypertension, targeting the renin‑angiotensin system and vascular smooth‑muscle tone.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertensive urgency: provides rapid, controlled reduction of elevated blood pressure when immediate treatment is required.
• Resistant hypertension: adds complementary mechanisms to achieve target blood pressure when monotherapy is insufficient.

• The combination product contains three agents that act synergistically: olmesartan medoxil blocks the angiotensin II type‑1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation; and hydrochlorothiazide promotes renal excretion of sodium and water, decreasing plasma volume. Together they lower peripheral resistance and cardiac output, resulting in sustained blood‑pressure reduction.

Side effects may occur with any antihypertensive regimen and vary in frequency.

Common Side Effects

• Dizziness or light‑headedness, especially after the first doses.
• Peripheral edema, often noticeable in the ankles.
• Headache, typically mild and transient.
• Flushing or warmth sensation.
• Fatigue or general tiredness.
• Increased urination due to the diuretic component.

Serious or Rare Side Effects

• Severe hypotension leading to fainting.
• Acute kidney injury manifested by sudden rise in creatinine.
• Electrolyte disturbances such as low potassium or sodium.
• Angio‑edema affecting the face, lips or airway.
• Liver enzyme elevations indicating hepatic stress.
• Allergic reactions ranging from rash to anaphylaxis.

When prescribing Olmesartan/Amlodipin/Hydrochlorthiazid Krka, clinicians should consider several safety aspects.

• Monitor blood pressure: ensure adequate control without excessive lowering.
• Assess renal function: check creatinine and electrolytes before and during therapy.
• Evaluate electrolytes: watch for hyponatremia or hypokalemia, especially with the thiazide component.
• Review cardiac status: caution in patients with severe aortic stenosis or heart failure.
• Pregnancy and lactation: avoid use; teratogenic risk is recognized for ARBs.
• Store at ambient temperature: keep below 25°C, protect from moisture and light, retain in original packaging.

Olmesartan/Amlodipin/Hydrochlorthiazid Krka can interact with several other medicines; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Concomitant use with aliskiren in patients with diabetes or renal impairment.
• Potassium‑rich supplements or potassium‑sparing diuretics, which may cause hyper‑kalemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) that increase amlodipine levels.

Moderate Interactions (Monitor Closely):

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may blunt antihypertensive effect.
• Lithium, as thiazides reduce renal clearance and raise lithium concentrations.
• Antidiabetic agents, since blood‑pressure reduction can enhance glucose‑lowering effects.
• Alcohol, which may increase dizziness and hypotensive response.
• Other antihypertensives, requiring dose adjustments to avoid excessive blood‑pressure fall.